Introduction

Multiple sclerosis (MS) is a chronic neurological disease, which usually begins in early adulthood. It causes repeated unpredictable bouts of motor disorders, partial paralysis, sensory abnormalities and visual impairment, with demyelination and gliosis, various degrees of axonal pathology and episodic or progressive neurological disability. The aetiology is unknown and complex, but results from an inflammatory process that, among other effects, attacks and destroys oligodendrocytes, the cells that form the myelin sheaths around axons in the brain and spinal cord [1]. The immunopathogenic phenomena leading to MS are thought to be triggered by environmental (viral?) factors operating on a predisposing genetic background.

Several viruses have been proposed as co-factors that may contribute to MS risk [2–3], by direct (acute or persistent) infection of the brain, or peripheral infection activating cross-reactive T-cells, acting against nerve myelin [4]. The most consistent studies (and confirmed by independent groups) for a potential virus involvement in MS exist for the Epstein Barr virus (EBV) [5–8], and for two members of the W family of human endogenous retroviruses (HERV-W): MSRV (MS associated retrovirus), and ERVW-1, an element expressing only the env protein, named Syncytin-1, as reviewed in [9–13].

The MSRV element (MS-associated retrovirus) is the first known member of the HERV-W family [14]; it has been detected and purified from cells of MS patients, as free virus-like particles, and for two members of the W family of human endogenous retroviruses (HERV-W): MSRV (MS associated retrovirus), and ERVW-1, an element expressing only the env protein, named Syncytin-1, as reviewed in [9–13].

The MSRV element (MS-associated retrovirus) is the first known member of the HERV-W family [14]; it has been detected and purified from cells of MS patients, as free virus-like particles, carrying RT activity and an RNA genome with terminal repeats, gag, pol and env regions. The other HERV-W member related to MS is an element located on chromosome 7q21–22, that has inactivating mutations in the gag and pol genes and is not able to form virus-like particles [15]. The env product of ERVW-1 has
been named syncytin-1, since it is produced by placental trophoblasts and causes their fusion, to form the syncytial layer during pregnancy [16]. The syncytin-1 protein can be found intracellularly and on the plasma membrane, but has not been detected extracellularly, nor its RNA sequence in virus-like particles [10].

Independent studies have shown that MSRVenv and syncytin-1 proteins share several potentially pathogenic, biological features, as induction of T-mediated immunopathology, of pro-inflammatory cytokines and T-cell responses, with polyovional expansion, as reviewed in [10–11], and have been shown to cause neurotoxic effects in vitro and in humanized or transgenic animal models [15,17]; they may cause neuroinflammation, neurodegeneration, alterations of the immune system and stress responses; both have been suggested as co-factors triggering the immuno-pathogenesis of MS. Expression of HERV-W/MSRV/syncytin-1 occurs in astrocytes of MS lesions of the brain [15,18–20], as well as in endothelial and microglial cells [21]. In a mouse model, oligodendrocytes (which produce the myelin sheath of the nerve) were shown to be sensitive to syncytin-mediated release of redox reactants from astrocytes [15].

Studies from our group found repeatedly retrovirus-like MSRV particles and MSRV-specific mRNA sequences in MS patients (in blood, spinal fluid, and brain samples), and MSRV presence/loads strikingly paralleled disease behaviour. A multicentre study of MS patients and controls from different European areas showed that MSRV presence and load in blood and spinal fluid was significantly associated to MS in all ethnic groups [22]. Direct parallelisms were observed between MSRV positivity/loads (in blood, spinal fluid, and brain samples) and MS temporal and clinical stages, as well as active/remission phases; moreover MSRV positivity of spinal fluids increased with MS duration [23]. Notably, MSRV presence in spinal fluids of early MS cases was related to worse prognosis in the next ten years: starting from comparable conditions, after three [24], six [25], and ten years [26], mean disability, annual relapse rate, therapy requirement and progression to secondary-progressive MS were significantly higher in patients starting with MSRV-positive spinal fluids. When we monitored MS patients receiving treatment, a major reduction of HERV-W/MSRV/syncytin-1 was detected in patients undergoing efficacious, current therapies [13,27]. Notably, in a longitudinal evaluation, a patient, after initial clinical and virological benefit, had MSRV rescue, preceding strong disease progression and therapy failure [27]. From the above findings, we proposed that evaluation of plasmatic MSRV could be considered the first prognostic marker for the individual patient, to monitor disease progression and therapy outcome. This possibility is reinforced by the study of patients with optic neuritis, a disease frequently prodromic to MS: MSRV positivity of patients was found significantly higher than that of pathological controls, and the conversion to full-blown MS in the next 20 months occurred only among MSRV-positive patients [28]. In line with our findings, an independent 1-year follow up study of MS patients observed significant decreases in anti-HERV-Wenv and anti-HERV-Henv antibody reactivity as a consequence of IFN-β therapy, closely linked to efficacy of therapy/low disease activity [29]. Other HERVs were reported to be activated in MS patients [3,9,12], However none of them, but HERV-W, has been shown to exert potentially neuro/pathogenic properties.

As for EBV, seroepidemiological studies have provided substantial support for the association between EBV and MS [5–8,30–31]. The risk of MS is low in EBV-negative individuals [32–34], and increases several folds following EBV infection, particularly if the EBV infection occurs in late adolescence or adulthood, when the infection is symptomatic. Indeed, in 35 to 50 per cent of the cases, the delayed EBV primary infection causes infectious mononucleosis (IM), that has been associated with a two-to-four fold increased risk of MS, [5,35–38]. There is also an increased risk of MS among EBV-positive children [39]. A meta-analysis showed an association between the appearance of anti-EBV antibodies and the MS onset, 5–20 years later [7]; another one reported that the relative risk of MS for a past history of IM is 2.17 [4]. In addition, elevated serum titres of pre-onset anti-EBNA antibodies have been associated with an increased risk of MS [35,40]. A recent meta-analysis of all data published from 1960 to 2012 showed a significant OR for sero-positivity to anti-EBNA (EBV nuclear antigens) IgG and anti-VCA IgG in MS cases, but not for anti-EA IgG sero-positivity [6]. Notably, high levels of anti-EBNA IgG antibody are established risk factors for MS [35].

There is convincing epidemiological evidence that late EBV primary infection/seroconversion is a risk factor for MS development, nevertheless, the relationship between EBV and MS pathogenesis remains elusive [4,30–31]. No studies have found yet evidence of EBV expression specific to MS, and currently there is no consensus in establishing whether there is a presence of EBV-infected cells in the central nervous system (CNS) of MS patients [30,41–42]. Therefore, it remains to be determined whether EBV would continue to play a role after disease initiation.

Several potentially pathogenic mechanisms explaining an EBV causative role for MS, yet very speculative, have been proposed, as recently reviewed [4,30]; they include molecular mimicry (generation of autoreactive T cells are primed against EBV, but cross-reacting with CNS antigens), and generation of EBV-infected autoreactive B cells (that would seed the target organ expressing the autoantigen and produce autoantibodies and costimulatory signals to autoreactive T cells).

Recently, we showed that the binding to the plasmamembrane of EBV/gp350, the major envelope protein of EBV, is sufficient to activate the potentially immunopathogenic and neuropathogenic HERV-W/MSRV/syncytin-1, in cells that may be involved in MS pathogenesis, deriving from blood and brain [13]. Hence, we made the hypothesis of a possible involvement of both viruses in MS pathogenesis, with the possibility for MSRV of a direct role of effector of pathogenicity, and for EBV of an initial trigger of future MS, years later. This “dual virus hypothesis” has been done also for torque teno virus [43], but an association between infection by this ubiquitous virus and MS could not be established so far [44].

Aim of the present study was to verify whether HERV-W activation by EBV might occur also in vivo, during a delayed primary infection by EBV, in young adults with IM symptoms requiring hospitalization. Indeed, the data indicate that the main links between EBV and MS (IM and high anti-EBNA-IgG titers) are paralleled by activation of the potentially neuropathogenic HERV-W/MSRV.

Materials and Methods

Ethics Statement

The study was approved by the Sassari ASL Ethics Committee (Protocol number 1120/L). The patients and the volunteers gave written informed consent. Written informed consent from the next of kin (which was one of the parents in all cases) on the behalf of minors (under the age of 10) was obtained.

Patients

Seventeen consecutive IM patients (mean age 23.2±5.7 years, median 22, 13 females and 4 males), hospitalized in the Section of
Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, were enrolled. Laboratory diagnosis of acute EBV infection was made by serological assays confirming the presence of EBV viral capsid antigen (VCA) IgM antibodies. For each patient, the data collected included type and duration of symptoms, family history for autoimmune diseases, including MS, neurological signs, routine IM-related clinical symptoms and signs, hematological values, and any steroid therapy. Serum EBV-specific IgG and IgM antibodies were detected by commercially available Chemiluminescence Immunoassays (CLIA), following manufacturer’s instructions (LIAISON® VCA IgG, IgM and EBNA-1 IgG, DiaSorin S.p.A. Vercelli, Italy). In most patients EBV DNA was evaluated in the plasma by real-time PCR (EBV ELITe MGB®34 Kit, according to the manufacturer’s protocols. Twenty four matched healthy donors (HD, mean age 26.2±4.8 years, median 25, 16 females and 8 males) were included as controls. Nine of them were EBV-negative, while fifteen had been infected by EBV previously. Of the latter, eight individuals had high levels of IgG antibody to the Epstein-Barr nuclear antigens (EBNA-1 IgG, titers >600 IU/ml). On Table 1 the most relevant demographic and clinical characteristics of hospitalized IM patients and of healthy controls are reported.

Blood Cell Separation
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized peripheral blood samples by layering on Ficoll/Hipaque, as described [27]. Cell viability was assessed with the Trypan blue exclusion method. The cells were either frozen in deep cold, or processed immediately for further studies (see below).

RNA Extraction and Real-time RT-PCR
The polyA+ RNAs were extracted from 50,000 cells, by mRNA Dynabeads® kit (Dynal Biotech, Oslo, NO) and retrotranscribed, as described [13]. Selective amplification of the MSRV-type HERV-Wenv transcripts was obtained by a discriminating real time RT-PCR assay, as published in [45]. The RNA amounts used for retrotranscription were 1.3 μg/sample, and the PCR temperature was 60°C. The quantification of cDNA sequences was obtained by external calibration curves, obtained from serial dilutions of plasmids containing the amplicon of interest (10-10^5 copies/well), as described previously [10]. The TaqMan® MSRVenv probe was designed by the Beacon Designer software (PREMIER Biosoft International CorinaWay Palo Alto, CA). To control for correct amplification and retrotranscription, a positive sample was also submitted to each RNA extraction procedure, and the resulting extract was amplified in triplicate. Parallel RNA samples were also exposed to PCR amplification without the RT step, to detect contaminant DNA. Prevention measures against cross-contamination were employed. For each sample, the Ct (cycle threshold) value of the gene of interest (GI) was normalized by comparison to the Ct of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) invariate housekeeping gene, assuming that (i) a difference of 1 between sample Cts means that the sample with the lower Ct value had double the target sequence of the other sample, and (ii) the rate of Ct change versus the rate of target copy change is identical for the gene of interest and the housekeeping gene, housekeeping gene. The data have been expressed according to the following formula:

\[ \text{MSRVenv relative amounts} = 2^{-\Delta Ct} \]

where

\[ \Delta Ct = Ct GI - Ct GAPDH \]

Flow Cytometry Analyses
Aliquots of 250,000 alive PBMC were employed for each evaluation. The detection of HERV-Wenv protein on the plasma membrane, as well as the phenotype of PBMC subpopulations, were performed by flow cytometry as described [13]. Briefly, the detection of HERV-Wenv protein on the plasma membrane was performed using anti-HERV-Wenv rabbit polyclonal antibody (Allele Biotec, 2 μg/sample, for 20 minutes at room temperature in the dark) and secondary fluorescein isothiocyanate-conjugated goat anti-rabbit IgG (Sigma-Aldrich). The isotype control was a pre-immune rabbit serum (Santa Cruz Biotechnology, Inc). To determine the phenotype of cell subpopulations, the PBMC were stained for 20 minutes at room temperature in the dark with allophycocyanin-conjugate anti-CD14, phycoerythrin-conjugated anti-CD19, and peridinin-chlorophyll-conjugated anti-CD16 antibodies (BD Biosciences). As isotype control, an anti-rabbit IgG antibody was used (Santa Cruz Biotechnology, Inc). Cells were analysed on a FACS Calibur flow cytometer, using Cells Quest software (Becton-Dickinson). The area of positivity was determined using an isotype-matched antibody; a total of at least 50,000 events for each sample were acquired.

Statistical Analysis
Descriptive statistics included mean, median, standard deviation (SD), interquartile range. The Shapiro-Wilks test was used to check the normality of the distribution. Between-group differences were assessed by using Kruskall Wallis and Mann–Whitney U-test for continuous nonnormally distributed variables, as appropriate. The relationship between nonparametric variables were evaluated calculating the Spearman’s correlation coefficient (rho) and its significance.

Results
Patient Characteristics
Blood samples of patients hospitalized with laboratory-confirmed diagnosis of IM were collected during the acute phase. Mean disease duration at the time of blood collection was 16.8±11.9 days from onset of symptoms, median 12 days, range 5–55 days. Eightytwo percent of the patients was in the first two weeks from IM onset, when the major immunologic and virological changes during primary EBV infection occur [46]. None of the patients or healthy controls had recognized risk of MS. The main characteristics of the study participants are reported on Table 1.

Expression of MSRVenv Transcripts
The relative quantification of MSRVenv transcripts in PBMC of patients and controls was carried out by MSRVtype-specific real-time RT-PCR [45]. Normalised data are reported on Figure 1: there is a statistically significant increase of MSRVenv transcripts in whole PBMC from IM patients with respect to healthy subjects (the median of IM patients is 6.9 fold higher than the one of healthy donors, p = 0.014).

Since high titers of anti-EBNA antibodies have been associated with increased risk of MS [35,40], the healthy donors were stratified according to their anti-EBNA-1 IgG titers, as uninfected
Table 1. Demographic and clinical characteristics of patients hospitalized with infectious mononucleosis and of healthy controls.

| Sample | Age  | Sex | Days from onset | Fever (°C) | VCA IgM (UI/ml) | VCA IgG (UI/ml) | EBNA-1 IgG (UI/ml) | EAlgG (UI/ml) | EBV DNA* |
|--------|------|-----|----------------|-----------|----------------|----------------|-------------------|-------------|----------|
| IM-1   | 18   | M   | 5              | 38.5      | >160           | 80             | neg               | 115         | <185     |
| IM-2   | 23   | F   | 8              | 40        | >160           | 126            | neg               | bl          | neg      |
| IM-3   | 19   | F   | 9              | 38.5      | 106            | 106            | neg               | neg         | nd       |
| IM-4   | 20   | F   | 10             | 39        | >160           | 146            | neg               | >150        | nd       |
| IM-5   | 23   | F   | 10             | 37.5      | >160           | 35             | neg               | bl          | neg      |
| IM-6   | 32   | F   | 10             | 38        | >160           | 33             | bl                | neg         | 5,725    |
| IM-7   | 22   | F   | 10             | 37.5      | 83             | 119            | neg               | 104         | nd       |
| IM-8   | 22   | F   | 12             | 39        | >160           | 195            | bl                | 69          | neg      |
| IM-9   | 23   | M   | 12             | 39        | 115            | 231            | neg               | >150        | 1,685    |
| IM-10  | 23   | F   | 15             | 38.5      | 49             | 21             | neg               | neg         | 225      |
| IM-11  | 21   | F   | 16             | 38        | >160           | 58             | bl                | 65          | <185     |
| IM-12  | 14   | F   | 17             | 39        | >160           | 108            | neg               | >150        | 180      |
| IM-13  | 22   | F   | 18             | 38        | Pos            | Pos            | Pos               | bl          | nd       |
| IM-14  | 27   | M   | 19             | 38.5      | >160           | 58             | neg               | 54          | 401      |
| IM-15  | 19   | F   | 23             | 38.2      | >160           | neg            | neg               | nd          | nd       |
| IM-16  | 40   | M   | 37             | 39.5      | 95             | neg            | neg               | neg         | neg      |
| IM-17  | 27   | F   | 55             | 37.5      | >160           | 345            | >600              | >150        | neg      |
| HD-1   | 20   | F   | –              | –         | –              | –              | Neg               | neg         | neg      |
| HD-2   | 21   | F   | –              | –         | –              | –              | Neg               | neg         | nd       |
| HD-3   | 22   | F   | –              | –         | –              | –              | Neg               | neg         | nd       |
| HD-4   | 23   | F   | –              | –         | –              | –              | Neg               | neg         | nd       |
| HD-5   | 23   | F   | –              | –         | –              | –              | Neg               | neg         | nd       |
| HD-6   | 27   | F   | –              | –         | –              | –              | Neg               | neg         | nd       |
| HD-7   | 31   | F   | –              | –         | –              | –              | Neg               | neg         | nd       |
| HD-8   | 31   | M   | –              | –         | –              | –              | Neg               | neg         | nd       |
| HD-9   | 32   | F   | –              | –         | –              | –              | Neg               | neg         | nd       |
| HD-10  | 20   | M   | –              | –         | –              | –              | Neg               | 483         | 157      |
| HD-11  | 21   | M   | –              | –         | –              | –              | Neg               | 137         | 246      |
| HD-12  | 23   | F   | –              | –         | –              | –              | Neg               | 158         | 48       |
| HD-13  | 23   | F   | –              | –         | –              | –              | Neg               | 143         | 142      |
| HD-14  | 26   | M   | –              | –         | –              | –              | Neg               | nd          | <600     |
| HD-15  | 28   | M   | –              | –         | –              | –              | Neg               | 81,3        | 289      |
| HD-16  | 29   | F   | –              | –         | –              | –              | Neg               | nd          | <600     |
| HD-17  | 23   | F   | –              | –         | –              | –              | Neg               | nd          | >600     |
| HD-18  | 23   | F   | –              | –         | –              | –              | Neg               | nd          | >600     |
| HD-19  | 25   | F   | –              | –         | –              | –              | Neg               | >750        | >600     |
| HD-20  | 26   | M   | –              | –         | –              | –              | Neg               | >750        | >600     |
| HD-21  | 29   | F   | –              | –         | –              | –              | Neg               | >750        | >600     |
| HD-22  | 29   | M   | –              | –         | –              | –              | Neg               | 176         | >600     |
| HD-23  | 35   | F   | –              | –         | –              | –              | Neg               | neg         | >600     |
| HD-24  | 39   | M   | –              | –         | –              | –              | Neg               | nd          | >600     |

*Data are expressed as EBNA-1 DNA copies/ml of plasma. Detection limits: 100 copies/ml of plasma;

bl, borderline;

nd, not done.

doi:10.1371/journal.pone.0078474.t001

(negative), or previously infected with low or high anti-EBNA-1 IgG titers (below or above 600 IU/ml of plasma, respectively). The data reported on Figure 1B indicate that the amounts of MSRVenv mRNA present in PBMC of healthy individuals are strictly related to those of anti-EBNA-1 IgG (p = 0.0005). However, the highest MSRVenv mRNA values are observed in the blood of IM patients, i.e. during the acute, highly symptomatic phase of the primary infection. In facts, the MSRVenv mRNA median value of IM patients is 194-fold higher that of uninfected persons; the values of persons with high and low anti-EBNA-1 IgG titers
Presence of the HERV-Wenv Protein on the Plasma Membrane

Due to the high percentage of identities between the HERV-Wenv genes, no antibody specific for a unique HERV-Wenv protein has been identified so far [13]. Therefore it cannot be discriminated whether an env protein is a MSRV-type env or syncytin-1, and data must be expressed as HERV-Wenv positivity only. Alive PBMC of four IM patients were analyzed by flow cytometry in comparison to four EBV-negative healthy individuals and four persons with past (latent) EBV infection and high anti-EBNA-1 IgG titers, with respect to the presence of HERV-Wenv protein on the outer surface of the plasma membrane. The analysis was limited to four individuals for each group, in order to compare only values collected in the same session, to avoid technical variations. The results are reported on Figure 2. As shown on Figure 2A, in whole PBMC the HERV-Wenv positivity of IM patients and of persons with past EBV infection is almost twice that of EBV-negative subjects. The HERV-Wenv protein, however, is not uniformly exposed by all the PBMC, but derives from an uneven expression in the various cell subsets. No statistical significance is reached in Figure 2A, since the main component of PBMC is the T cell compartment, that was previously shown to be totally negative for HERV-Wenv expression, both at the protein and at the RNA level [13,47]; therefore it was not analysed specifically. However, no HERV-Wenv expression was detected on the plasma membrane of CD19−/CD16+CD14+ cells, that comprises the T cells (data not shown). As shown in Panels 2B–D, in uninfected individuals the median HERV-Wenv positivity of CD19+, CD16+ and CD14+ cells (B lymphocytes, NK cells and monocytes, respectively) is around 19, 10 and 17%, respectively. The env positivity of the CD19+ B cell compartment (Figure 2B) is more than doubled after EBV infection (IM patients: 43%, latently infected highly anti-EBNA-1 positive individuals: 36%, p = 0.043). As for the CD16+ NK cell subset (Figure 2C), there is a 4-fold increase in HERV-Wenv expression during IM (40%, p = 0.020), but a deep reduction in latently infected highly anti-EBNA-1 positive individuals: 3%). The CD14+ monocyte compartment (Figure 2D) showed the highest increases of HERV-Wenv expression: 5.4-fold increase during IM (mean positivity: 92%, p = 0.045) and 2.6-fold increase during highly anti-EBNA-1 positive latency (44%; also the difference between the latter two group reaches the statistical difference (p = 0.021).

Discussion

A history of IM and high anti-EBV titers are factors that increase the risk of MS [5,7–8,35–38,40]. The mechanism by which EBV infection is linked to MS pathogenesis is still unknown [4,30–31]. No studies support unequivocally a direct etiologic role of EBV or prove its preferential presence, expression or reactivation in MS patients with respect to controls to MS, and currently there is no consensus in establishing whether there is a presence of EBV-infected cells in the CNS of MS patients [30,41–42]. Therefore, it remains to be determined whether EBV would continue to play a role after disease initiation.

On the other hand, potentially neuropathogenic endogenous retroviruses of the W family are expressed in the blood and in the brain of MS patients in close parallelism with disease progression [23,26–27]. Recently we have found a link between EBV and HERV-W, since we showed that the binding in vitro to the plasmamembrane of the EBV gp350 major envelope protein is able to activate the expression of the potentially immunopathogenic and neuropathogenic HERV-Ws in in cells that may be involved in MS pathogenesis (B cells, monocytes, macrophages and astrocytes) [13]. Hence, we made the dual virus hypothesis of a possible involvement of both viruses in MS pathogenesis, with the possibility for MSRV of a direct role of effector of pathogenicity, and for EBV of an initial trigger of future MS, years later.

In the present report, we provide for the first time data showing that activation of HERV-W/MSRV occurs in vivo in patients affected by IM. With respect to EBV-negative healthy controls, the increase of MSRV-type env mRNAs in IM patients is almost 2 Log10 (p = 0.000006, Figure 1B). More interestingly, when healthy controls are stratified with respect to previous EBV infection (high and low, or no anti-EBNA-1 IgG titers), a close correlation occurs for MSRV mRNA activation (Sperman rho = 0.60, p<0.05).
These novel findings are reinforced by the flow cytometry data on the activation also of the HERV-Wenv protein product, reported in Figure 2 as the percentage of PBMC expressing the HERV-Wenv protein on the membrane. The HERV-W activation is not uniform in all cell subtypes nor in acute disease and past infection, i.e. the latency state (Figures 2B–D). With respect to uninfected healthy individuals, IM patients showed a doubling of HERV-W positivity of B cells, and 4-fold and 5.5-fold increases in NK cells and monocytes, respectively. In past infection with high anti-EBNA-1 IgG titers, B cells continue to express similar HERV-Wenv levels, while the effect is reduced on monocytes (2.6-fold higher than in uninfected individuals), and NK cells became almost HERV-Wenv-negative. We have no explanation for the latter finding. On the whole, the data indicate that post-transcriptional regulation of HERV-Wenv occurs differently in specific cell subsets, in keeping with our previous observations [13].

Thus in our hands both ascertained links between EBV and risk of future MS (IM and high anti-EBNA-1 titers) do stimulate the expression of HERV-W/MSRV.

As for the mechanisms of HERV-W activation, we showed recently that in vitro EBV activates HERV-W/MSRV/syncytin-1, in cells from blood and brain, that might be involved in the pathogenesis of MS [13]. There is no need of EBV entry or expression, since the effect was seen also after exposure to the EBVgp350 major envelope protein. In EBVgp350-treated PBMC, MSRV<sub>env</sub> and syncytin-1 transcription was activated in B cells and monocytes, but not in T cells (that do not express HERV-W genes), nor in the highly positive NK cells. The latter cells (as the monocytes and the B, but not the T cells) were activated by proinflammatory cytokines, likely with involvement of the protein kinase C signalling enzyme [13]. The effect of EBV<sub>gp350</sub> was abolished by silencing NF-κB, a transcription factor that is implicated in the production, by activated astrocytes, of proinflammatory cytokines: this, in turn, induces further release of cytokines, that contribute in vivo to exacerbating the neurodegenerative process [48], and that in vitro stimulate HERV-W<sub>env</sub> expression in astrocytes (unpublished data) and PBMC [13, 49]. It is likely that in vivo, during EBV replication in IM patients, the EBVgp350 protein could activate HERV-W/MSRV expression, as we showed in vitro [13]. In addition, a cytokine-mediated mechanism could cooperate with EBV for HERV-W activation. As known, several cytokines are produced during acute IM. In a prospective study of late primary EBV infections, Ballfour et al. [46], detected elevated levels of eight cytokines that might contribute to IM pathogenesis, among which interferonγ, TNFα, and IL-6; the latter was correlated significantly with IM severity and high EBV viremia. Of note, IL-6 is a major cytokine in the central nervous system, that has been related to many brain diseases, among which MS [50]. The above cytokines do increase HERV-W expression/release in vivo [13, 49], and are increased in vivo during MS exacerbations [50].
Of particular interest is the effect of EBV activation of HERV-W/MSRV in the vast majority of monocytes during the acute infection (Figure 2D, IM), for possible involvements in MS pathogenesis. In vivo, these cells were shown to be the most responsive to EBVpp350, reaching, after exposure to the EBV protein, HERV-W levels higher than those detected in B cells, particularly after cell differentiation into macrophages [13]. In MS, and other neurological diseases, significant infiltration of immune cells from the periphery into the CNS (and activation of microglia) is largely observed, and it accounts for the increased representation of macrophages within the CNS; the functions of activated macrophages (and microglia) within the CNS are complex, as they are implicated in both demyelination and remyelination of MS lesions, as observed in animal models [51]. Increased blood-brain barrier permeability is a characteristic hallmark of the CNS alterations leading to MS, suggesting a causal relationship between inflammatory cell recruitment into the CNS and the blood–brain barrier dysfunction [52]. Activated monocytes easily pass across the endothelia, and could carry the HERV-W across the blood–brain barrier, entering the brain, where the HERV-Wenv protein could contribute to the pathogenicity, inducing inflammation, demyelination and axonal damage [6,10–13]. Thus, the HERV-W expression (and release) by monocyte-macrophages can reasonably account for the bulk of expression (and effects) of these elements. Also the high levels of HERV-W expression in B cells throughout the IM and the post-infection stages (Figure 2B), as well as in MS patients [13] might contribute to the process, since B cells have been proposed to be relevant to the etiology and pathogenesis of MS [53], and MS therapies targeting B cells seem effective against the relapsing-remitting forms [54].

As for the post-infection stages of EBV latency, it is well known that during latency, EBV expresses a limited repertoire of proteins, non-coding RNAs and microRNAs [54]. The virus remains immunologically silent in small numbers of memory B cells, which traffic into inflamed tissues, and are tightly controlled by invariant natural killer T cells [55] and by cytotoxic T lymphocyte cells to prevent lymphoproliferation [56]. Since HERV-W is expressed by a high proportion of B cells (Figure 2B), it is likely that reciprocal interactions occur within these cells during latency, that could play an additional role to the indirect mechanism proposed by Meier and coworkers, by which latent EBV infection could contribute to (neuro)inflammation, through the expression of small non-coding RNAs that bind to Toll-like receptor 3 and potentially other intracellular receptors [56]. Notably, EBNA-1 is the only viral protein commonly expressed in latency programs that allow the persistence of EBV in B-cells during activation and differentiation and in a variety of other cells types, and this protein has been shown to reprogram cellular transcription and signaling [58–59]. Moreover, its binding to several cellular promoters has been documented [60]. Therefore a contribute of EBNA-1 to HERV-W activation in these cells could be hypothesized, either by direct HERV-W activation in circulating B cells, or indirectly, through induction of HERV-W-activating stimuli. A major issue of the present paper is not only the finding that HERV-W is activated during IM, but also that it is observed in a subset of healthy, latently-infected individuals (those with antiEBNA-1 titers >600). A long prospective study showed that elevations of antibody titers to the EBNA complex and EBNA-1 among MS cases first occurred between 15 to 20 years before the onset of symptoms and persisted thereafter [57]. We show here that high HERV-W expression occurs in healthy persons with high anti-EBNA IgG titers, thus concomitantly to what has been considered among the early events in the pathological process that leads to MS, perhaps in individuals presenting a predisposing genetic background.

In conclusion, our data indicate that the two main links of EBV to MS (past IM and high anti-EBNA-1 IgG titers) are associated to the activation of potentially neuropathogenic HERV-W/MSRV, both at the mRNA and the protein levels. These novel findings reinforce our hypothesis of a possible involvement of both viruses in MS pathogenesis [13], with the possibility for MSRV of a direct role of effector of pathogenicity, and for EBV of an initial trigger of future MS, years later, and indicate the activation of HERV-W/MSRV as the possible missing link between EBV and MS. These findings may open new avenues of intervention against MS.

Acknowledgments

The authors wish to thank all patients and volunteers whose participation enabled this study.

Author Contributions

Conceived and designed the experiments: AD G. Mameli G. Madeddu MSM. Performed the experiments: AM LP EU CS RM. Analyzed the data: AD G. Mameli G. Madeddu RM LGD SB IM. Perfomed the statistical analysis: G. Madeddu. Conducted the clinical and laboratory studies: MSM SB IM. Performed the reagents/materials/analysis tools: CS RM LGD G. Mameli G. Madeddu. Wrote the paper: AD. Advised and edited manuscript: AD G. Mameli G. Madeddu MSM SB IM. Approved the final version of the manuscript: AD G. Mameli G. Madeddu.

References

1. McQuater JL, Bernard CC (2007) Multiple sclerosis: a battle between destruction and repair. J Neurochem 100: 295–306.
2. Kakacheva K, Minz G, Linnenmann JD (2011) Viral triggers of multiple sclerosis. Biochim Biophys Acta 1812: 132–140.
3. Christensen T (2010) HERVs in neuropathogenesis. J Neuroimmune Pharmacol 5: 326–335.
4. Csak MF, Libby JE, Fujimami RS (2013) Multiple sclerosis: autoimmune and viruses. Curr Opin Rheumatol 25: 496–501.
5. Ascherio A, Munger KL (2010) Epstein-Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 5: 271–277.
6. Almohamed YH, Avenell A, Aucott L, Vickers MA (2013) Systematic Review and Meta-Analysis of the Sero-Epidemiological Association between Epstein Barr Virus and Multiple Sclerosis. PLoS One 8: e61110.
7. Santiago O, Gutierrez J, Soezolano A, De Dios Luna J, Villegas E, et al. (2010) Relation between Epstein-Barr virus and multiple sclerosis: a study of scientific production. Eur J Clin Microbiol Infect Dis 29: 857–866.
8. Handel AE, Williamson AJ, Di Santo G, Handunnetthi L, Giovannoni G, et al. (2010) An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One 5: e12496.
9. Dolei A (2006) Endogenous retroviruses and human disease. Exp Rev Clin Immunol 2: 149–167.
10. Dolei A, Perron H (2009) The multiple sclerosis-associated retrovirus and its HERV-W endogenous family: a biological interface between virology, genetics, and immunology in human physiology and disease. J Neurovirol 15: 4–13.
11. Perron H, Lang A (2010) The Human Endogenous Retrovirus Link between Genes and Environment in Multiple Sclerosis and in Multifactorial Diseases Associating Neuroinflammation. Clinic Rev Allerg Immunol 39: 51–61.
12. Antony JM, Deslauriers AM, Bhat RK, Ellestad KK, Power C (2011) Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants? Biochem Biophys Acta 2: 162–176.
13. Mameli G, Paddige L, Mei A, Uleri E, Sotgia S, et al. (2012) Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis. PLoS One 7: e44991.
14. Perron H, Gason JA, Bedin F, Bexere F, Paranhos-Racca G, et al. (1997) The Collaborative Research Group on Multiple Sclerosis: Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. Proc Natl Acad Sci USA 94: 7503–7508.
15. Antony JM, Van Male G, Opi W, Butterfield DA, Mallet F, et al. (2004) Human endogenous retrovirus glycoprotein-mediated induction of redox reagents causes oligodendrocyte death and demyelination. Nat Neurosci 7: 1088–1095.
36. Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D (2004) Multiple sclerosis following Epstein-Barr virus infection: a case–control study. J Neurol 251: 758–763.

35. Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D (2004) Multiple sclerosis following Epstein-Barr virus infection: a case–control study. J Neurol 251: 758–763.

34. Pakpoor J, Disanto G, Gerber JE, Dobson R, Meier UC, et al. (2013) The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler 19: 162–166.

33. Mungur K, Levin L, O'Reilly E, Falk K, Ascherio A (2011) Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 17: 1185–1193.

32. Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D (2004) Multiple sclerosis following Epstein-Barr virus infection: a case–control study. J Neurol 251: 758–763.

31. Mungur K, Levin L, O'Reilly E, Falk K, Ascherio A (2011) Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 17: 1185–1193.

30. Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D (2004) Multiple sclerosis following Epstein-Barr virus infection: a case–control study. J Neurol 251: 758–763.

29. Mungur K, Levin L, O'Reilly E, Falk K, Ascherio A (2011) Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 17: 1185–1193.

28. Sotgiu S, Arru G, Mameli G, Serra C, Zarbo IR, et al. (2010) Epstein-Barr virus and multiple sclerosis. J Infect Dis 207: 80–88.

27. Mameli G, Poddighe L, Astone V, Castellazzi M, Delogu G, et al. (2009) Novel reliable real-time PCR for differential detection of MSRveno and syncytin-1 in RNA and DNA from patients with multiple sclerosis. J Virol Methods 161: 98–106.

26. Sotgiu S, Mameli G, Serra C, Zarbo IR, Arru G, et al. (2010) Epstein-Barr virus and multiple sclerosis. J Infect Dis 207: 80–88.

25. Sotgiu S, Arru G, Mameli G, Serra C, Pugliatti M, et al. (2006) MSRV in early multiple sclerosis: a six-year follow-up of a Sardinian cohort. Mult Scler 12: 1721–1736.

24. Sotgiu S, Arru G, Mameli G, Serra C, Pugliatti M, Rosati G, et al. (2002) Multiple sclerosis-associated retrovirus and MS prognosis: an observational study. Neurology 59: 1071–1073.

23. Dolei A, Serra C, Mameli G, Pugliatti M, Sechi S, et al. (2002) Multiple sclerosis and HERV-W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler 8: 1721–1736.

22. Arru G, Mameli G, Astone V, Serra C, Huang YM, et al. (2007) Multiple sclerosis and HERV-W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler 8: 1721–1736.

21. Perron H, Lazarini F, Ruprecht K, Pechoux-Longin C, Seilhean D, et al. (2005) Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis. J Neuroimmunol 169: 23–33.

20. Perron H, Germi R, Bernard G, Garcia-Montojo M, Delaux C, et al. (2012) Epstein-Barr virus stimulates toro tenu virus replication: a possible relationship to multiple sclerosis. PLoS One 7:e32160.

19. Bhat RK, Ellestad KK, Wheatley BM, Warren R, Holt RA, et al. (2001) Age-related expression of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Mult Scler 7: 1032–1035.

18. Firouzi R, Rolland A, Michiel M, Jousin-Marie E, Haase JJ, et al. (2003) Multiple sclerosis-associated retrovirus particles cause T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. J Neurovir 9: 79–93.

17. Blat KK, Elssett KK, Wheatley BM, Warren R, Holt RA, et al. (2001) Age- and disease-dependent HERV-W envelope allelic variation in brain: association with neuroimmunome gene expression. PLoS One 6:e19176.

16. Mi S, Lee X, Li X, Veldman GM, Finnerty H, et al. (2000) Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 403: 785–789.

15. Mameli G, Serra C, Astone V, Zarbo IR, Sotgiu S, et al. (2006) Multiple sclerosis-associated retrovirus particles cause T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. J Neurovir 9: 79–93.

14. Mameli G, Astone V, Zarbo IR, Sotgiu S, Serra C, et al. (2007) Multiple sclerosis and HERV-W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler 13: 1071–1073.

13. Sotgiu S, Mameli G, Serra C, Zarbo IR, Sotgiu S, et al. (2006) Multiple sclerosis and HERV-W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler 12: 1721–1736.

12. Sotgiu S, Arru G, Mameli G, Serra C, Pugliatti M, et al. (2006) MSRV in early multiple sclerosis: a six-year follow-up of a Sardinian cohort. Mult Scler 12: 698–703.

11. Sotgiu S, Mameli G, Serra C, Zarbo IR, Arru G, et al. (2010) Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis. Mult Scler 16: 1249–1251.

10. Mameli G, Serra C, Astone V, Castellazzi M, Poddighe L, et al. (2008) Inhibition of multiple sclerosis-associated retrovirus as biomarker of interferon therapy. J Neurol 255: 73–77.

9. Sotgiu S, Arru G, Soderstrom M, Mameli G, Serra C, et al. (2006) MSRV and optic neuritis. Mult Scler 12: 357–359.

8. Petersen T, Moller-Larsen A, Thiel S, Brudet T, Hansen TK et al. (2009) Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytotoxic production, and the lectin complement activation pathway in multiple sclerosis. J Neuroimmunol 215: 108–116.

7. Sotgiu S, Arru G, Mameli G, Serra C, Pugliatti M, et al. (2006) MSRV in early multiple sclerosis: a six-year follow-up of a Sardinian cohort. Mult Scler 12: 698–703.

6. Sotgiu S, Mameli G, Serra C, Zarbo IR, Arru G, et al. (2010) Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis. Mult Scler 16: 1249–1251.

5. Mameli G, Serra C, Astone V, Castellazzi M, Poddighe L, et al. (2008) Inhibition of multiple sclerosis-associated retrovirus as biomarker of interferon therapy. J Neurol 255: 73–77.

4. Sotgiu S, Arru G, Soderstrom M, Mameli G, Serra C, et al. (2006) MSRV and optic neuritis. Mult Scler 12: 357–359.

3. Petersen T, Moller-Larsen A, Thiel S, Brudet T, Hansen TK et al. (2009) Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytotoxic production, and the lectin complement activation pathway in multiple sclerosis. J Neuroimmunol 215: 108–116.

2. Sotgiu S, Arru G, Mameli G, Serra C, Pugliatti M, et al. (2006) MSRV in early multiple sclerosis: a six-year follow-up of a Sardinian cohort. Mult Scler 12: 698–703.

1. Sotgiu S, Mameli G, Serra C, Zarbo IR, Arru G, et al. (2010) Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis. Mult Scler 16: 1249–1251.